ESCRS - PO0519 - Patient-Reported Outcomes For Visual Disturbances With An Extended Depth Of Focus Intraocular Lens: A Meta-Analysis

Patient-Reported Outcomes For Visual Disturbances With An Extended Depth Of Focus Intraocular Lens: A Meta-Analysis

Published 2023 - 41st Congress of the ESCRS

Reference: PO0519 | DOI: 10.82333/mq4g-zs03

Authors: Jesse Vislisel 1 , Jun Zhang 2 , Mukesh Dhariwal 2 , Li-Chen Pan* 3

1Associated Eye Care,Stillwater, Minnesota,United States, 2Alcon,Fort Worth, Texas,United States, 3Global Market Access,Alcon Vision, LLC ,Fort Worth,United States

Approved by the FDA in 2020, AcrySof IQ Vivity (DFTXXX/DATXXX) is an extended depth of focus (EDOF) IOL designed to provide a monofocal-like visual disturbance profile. A proportional meta-analysis of recently published evidence was conducted to evaluate the patient-reported visual disturbances after bilateral implantation of DFTXXX/DATXXX IOLs.

Global literature review

PubMed, AAO, APACRS, APAO, ASCRS, ESCRS congresses and Alcon internal database were searched from April 2021 to December 2022. Fifteen studies (11 peer-reviewed, 2 congress papers, and 2 unpublished reports) analyzing patient-reported visual disturbances among individuals implanted with DFTXXX/DATXXX were included. Other inclusion criteria were bilateral implantation, randomized or observational studies, and final results reporting follow-up of 1 or more months. Fixed and random effects meta-analyses were conducted using the “meta” package of R software, providing pooled proportions for patient-reported visual disturbances with a 95% confidence interval [CI]. 

Ten prospective observational studies, four RCTs, and one registry were included. The studies included 1261 DFTXXX/DATXXX patients from 10 different countries with follow-up periods ranging from 3 months to >12 months. Patient-reported visual disturbances were obtained using QUVID (n=4), Quality of Vision (n=4), NEI-VFQ-25 (n=1), and unidentified questionnaires (n=6). In random effects meta-analysis, some patients experienced glare (21.3% [12.7–31.2%]; n=1260), halos (20.3% [12.3–29.6%]; n=1261), or starbursts (12.2% [4.6–22.2%]; n=1186). Only 0.8%, 0.1% and 0.9% of patients experienced severe or most bothersome glare (n=1103), halos (n=1104) or starbursts (n=1084), respectively.  

This study demonstrated that some patients experienced visual disturbances with bilateral implantation of DFTXXX/DATXXX EDOF IOL, and severe visual disturbances were very uncommon. These results help patients and providers make informed decisions when selecting an IOL for cataract surgery.